Advertisement

Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Organisation › Details

InflaRx GmbH

InflaRx is a biopharmaceutical company focusing on the development of new therapeutics controlling the inflammatory response based on its proprietary technology.. InflaRx has developed a pipeline of first-in-class antibodies directed against the terminal complement component C5a. While IFX-1 focuses on the acute care space, its product candidates, IFX-2 and IFX-3, are being developed in chronic inflammatory disease indications. InflaRx was founded in 2007 and is headquartered in Jena, Germany, with long standing research collaborations in the US and China. The team consists of renowned experts in complement research and clinical acute care. InflaRx is privately owned and financed by bm-t Beteiligungsmanagement Thüringen Gmbh, KfW banking group and various international family offices. *

 

Period Start 2007-01-01 established
  Group InflaRx (Group)
Products Industry anti-inflammatory drug
  Industry 2 IFX-1 (InflaRx)
Persons Person Riedemann, Niels C. (InflaRx 200803 Managing Director + founder)
  Person 2 Christ, Arnd (Immatics 202010– CFO before InflaRx + Proteros + MediGene + NovImmune + Probiodrug + Hoechst)
     
Region Region Jena
  Country Germany
  Street 2 Winzerlaer Str.
  City 07745 Jena
  Tel +49-3641-508180
    Address record changed: 2020-12-12
     
Basic data Employees n. a.
     
    * Document for �About Section�: 
     
   
Record changed: 2020-12-12

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for InflaRx (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px




» top